… a CD34 + selected or an un-manipulated graft has the lowest … , and their role if any in 2ndADs
(or relapse), has not been … mature naïve B cells and persistent decrease in memory B cells …

… unmanipulated autologous HCT with CD34-selected … 2% in the auto-HCT group with HR for
time to first relapse 0.097. … death, or the development of persistent major organ failure of the …

… disease-modifying therapies (DMTs), reflecting the persistent … Several phase II clinical
trials supported the early notion that … Autologous stem cell transplantation aids autoimmune …

… However the possible persistence of minimal residual autoimmune disease cannot be …
Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem …

… , and no recurrence of disease symptoms was documented after halting … persistence of
auto-reactive cells after transplantation or de novo emergence of the autoimmune diseases …

… autoimmune diseases, including autoimmune neurological … the graft may be reinfused
unmanipulated or after ex-vivo purging … tested, indicating the persistence of the pathogenetic B cell …

… to treat aggressive autoimmune diseases and, among them, … similar high efficacy after
AHSCT, with relapse-free survival of … These symptoms persist in only a minority of patients. …

… with high levels of persistent inflammatory activity with rapidly … activity (at least 2 clinical
relapses, or one clinical relapse with … In MS, both unmanipulated and manipulated autologous …

… high rates of persistent or relapse of disease activity within 6 … relapse rate is higher in patients
receiving unmanipulated … (autologous in 93% of cases) for autoimmune indications have …

… the effectiveness of aHSCT in autoimmune diseases, especially with regard to long term …
-responders and patients with relapse in the first three years following aHSCT. We defined this …